BioSyent Announces Long-term Extension of Cathejell® Agreement
June 20 2023 - 7:30AM
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is
pleased to announce that its wholly-owned subsidiary, BioSyent
Pharma Inc. (“BioSyent Pharma”), has extended its License,
Distribution and Supply Agreement with its European partner for the
Cathejell® product, extending BioSyent Pharma’s exclusive Canadian
rights to Cathejell® until 2034.
“We have had considerable success with
Cathejell® since launching this product in Canada in 2012,”
commented René Goehrum, President and CEO of BioSyent. “Cathejell®
has been a consistent contributor to our specialty products
portfolio and we look forward to continuing to serve our hospital
and urology customers over the long-term with this trusted
product.”
About
Cathejell®
Cathejell® combines a sterile gel with lidocaine
in a unique collapsible applicator syringe to ease patient
discomfort for a range of medical procedures. Cathejell® is
indicated for surface anesthesia and lubrication for various
procedures including male and female cystoscopies, catheterizations
and other endourethral operations, endoscopies, proctoscopies,
rectoscopies and tracheal intubations. Cathejell® can also be used
for the symptomatic treatment of pain in connection with cystitis
and urethritis.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community, specialty
and international business units.
As of the date of this press release, the
Company has 11,981,319 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
This press release may contain information or
statements that are forward-looking. The contents herein represent
our judgment, as at the release date, and are subject to risks and
uncertainties that may cause actual results or outcomes to be
materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to,
those associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024